Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more

Recent & Breaking News (GREY:NAVB)

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

GlobeNewswire June 15, 2020

Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series

GlobeNewswire June 9, 2020

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress

GlobeNewswire June 3, 2020

Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

Business Wire May 21, 2020

Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results

Business Wire May 14, 2020

Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®

Business Wire May 11, 2020

Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update

Business Wire May 7, 2020

Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic

Business Wire April 22, 2020

Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea's Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates

Business Wire March 31, 2020

Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®

Business Wire March 20, 2020

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Business Wire March 11, 2020

Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update

Business Wire March 4, 2020

Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Business Wire February 14, 2020

Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding

Business Wire February 14, 2020

Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York

Business Wire December 30, 2019

Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

Business Wire December 5, 2019

Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

Business Wire December 2, 2019

Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

Business Wire November 14, 2019

Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

Business Wire November 7, 2019

Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

Business Wire November 7, 2019